M. H. Barcellos-Hoff, “Does Microenvironment Contribute to the Etiology of Estrogen Receptor-Negative Breast Cancer?” Clinical Cancer Research, Vol. 19, No. 3, 2013, pp. 541-548.
 N. A. Saunders, F. Simpson, E. W. Thompson, M. M. Hill, L. Endo-Munoz, G. Leggatt, R. F. Minchin and A. Guminski, “Role of Intratumoural Heterogeneity in Cancer Drug Resistance: Molecular and Clinical Perspectives,” EMBO Molecular Medicine, Vol. 4, No. 8, 2012, pp. 675-684. http://dx.doi.org/10.1002/emmm.201101131
 K. R. Kutanzi, O. V. Yurchenko, F. A. Beland, V. F. Checkhun and I. P. Pogribny, “MicroRNA-Mediated Drug Resistance in Breast Cancer,” Clinical Epigenetics, Vol. 2, No. 2, 2011, pp. 171-185.
 T. A. Farazi, J. I. Hoell, P. Morozov and T. Tusch, “MicroRNAs in Human Cancer,” Advances in Experimental Medicine and Biology, Vol. 774, 2013, pp. 1-20.
 P. Karihtala and Y. Soini, “Reactive Oxygen Species and Antioxidant Mechanisms in Human Tissues and Their Relation to Malignancies,” APMIS, Vol. 115, No. 2, 2007, pp. 81-103.
 H. Wiseman and B. Halliwell, “Damage to DNA by Reactive Oxygen and Nitrogen Species: Role in Inflammatory Disease and Progression to Cancer,” Biochemical Journal, Vol. 313, No. 1, 1996, pp. 17-29.
 S. I. Shpyleva, V. P. Tryndyak, O. Kovalchuk, A. Starlard-Davenport, V. F. Chekhun, F. A. Beland and I. P. Pogribny, “Role of Ferritin Alterations in Human Breast Cancer Cells,” Breast Cancer Research and Treatment, Vol. 126, No. 1, 2011, pp. 63-71.
 K. Fan, L. Gao and X. Yan, “Human Ferritin for Tumor Detection and Therapy,” Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, Vol. 5, No. 4, 2013, pp. 287-298. http://dx.doi.org/10.1002/wnan.1221
 C. Datz, T. K. Felder, D. Niederseer and E. Aigner, “Iron Homeostasis in the Metabolic Syndrome,” European Journal of Clinical Investigation, Vol. 43, No. 2, 2013, pp. 215-224. http://dx.doi.org/10.1111/eci.12032
 M. Geppert, M. C. Hohnholt, S. Nürnberger and R. Dringen, “Ferritin Up-Regulation and Transient ROS Production in Cultured Brain Astrocytes after Loading with Iron Oxide Nanoparticles,” Acta Biomaterialia, Vol. 8, No. 10, 2012, pp. 3832-3839.
 V. F. Chekhun, N. Yu. Lukianova and N. O. Bezdene- zhnykh, “Features of Iron Metabolism Regulatingproteins Expression in Sensitive and Resistant to Antitumor Drugs Breast Cancer Cells in Vitro,” Clinical Oncology (SE), Proceedings of XII Ukrainian Oncologists Meeting, Sudak, 2011, p. 227.
 N. Kikyo, M. Suda, N. Kikyo, K. Hagiwara, K. Yasukawa, M. Fujisawa, Y. Yazaki and T. Okabe, “Purification and Characterization of a Cell Growth Factor from a Human Leukemia Cell Line: Immunological Identity with Ferritin,” Cancer Research, Vol. 54, No. 1, 1994, pp. 268-271.
 E. Laqué-Rupérez, M. J. Ruiz-Gómez, L. de la Pena, L. Gil and M. Martínez-Morillo, “Methotrexate Cytotoxicity on MCF-7 Breast Cancer Cells Is Not Altered by Exposure to 25 Hz, 1.5 mT Magnetic Field and Iron (III) Chloride Hexahydrate,” Bioelectrochemistry, Vol. 60, No. 1-2, 2003, pp. 81-86.
 J. F. Head, F. Wang and R. L. Elliott, “Antineoplastic Drugs That Interfere with Iron Metabolism in Cancer Cells,” Advances in Enzyme Regulation, Vol. 37, 1997, pp. 147-169.
 S. V. Torti and F. M. Torti, “Cellular Iron Metabolism in Prognosis and Therapy of Breast Cancer,” Critical Reviews in Oncogenesis, Vol. 18, No. 5, 2013, pp. 435-448.
 J. L. Heath, J. M. Weiss, C. P. Lavau and D. S. Wechsler, “Iron Deprivation in Cancer-Potential Therapeutic Implications,” Nutrients, Vol. 5, No. 8, 2013, pp. 2836-2859.
 Y. L. Chao, C. R. Shepard and A. Wells, “Breast Carcinoma Cells Re-Express E-Cadherin during Mesenchymal to Epithelial Reverting Transition,” Molecular Cancer, Vol. 9, No. 1, 2010, pp. 179-197.
 R. A. McCelland, D. Wilson and R. Leake, “A Multicentre Study into the Reliability of Steroid Receptor Immunocyto-Chemical Assay Quantification,” European Journal of Cancer, Vol. 27, 1991, pp. 711-715.
 V. F. Chekhun, O. V. Yurchenko, L. A. Naleskina, D. V. Demash, N. Yu. Lukianova and Yu. V. Lozovska, “In Vitro Modification of Cisplatin Cytotoxicity with Magnetic Fluid,” Experimental Oncology, Vol. 35, No. 1, 2013, pp. 15-19.
 N. Yu. Lukyanova, N. V. Rusetskаya and N. A. Tregubova, “Moleсular Profile and Cell Cycle in MCF-7 Cells Resistant to Cisplatin and Doxorubicin,” Experimental Oncology, Vol. 31, No. 2, 2009, pp. 87-92.
 H. Tanaka, H. Arakawa, T. Yamaguchi, K. Shiraishi, S. Fukuda, K. Matsui, Y. Takei and Y. Nakamura, “A Ribonucleotide Reductase Gene Involved in a p53-Dependent Cellcycle Checkpoint for DNA Damage,” Nature, Vol. 404, 2000, pp. 42-49.
 D. S. Byun, K. S. Chae, B. K. Ryu, M. G. Lee and S. G. Chi, “Expression and Mutation Analyses of P53R2, a Newly Identified p53 Target for DNA Repair in Human Gastric Carcinoma,” International Journal of Cancer, Vol. 98, No. 5, 2002, pp. 718-723.
 N. Yu. Lukianova, L. A. Naleskina, N. O. Bezdenezhnykh, L. M. Kunskaya, D. V. Demash, Yu. V. Yanish, I. M. Todor and V. F. Chekhun, “Reactive Changes of Cytophysiological Properties, Molecular-Biological Profile and Functional Metabolic Status of Cells in Vitro with Different Sensitivity to Cytostatic Agents under the Influence of Magnetic Fluid,” Journal of Cancer Research, Vol. 1, No. 1, 2013, pp. 7-14.
 H.-J. Kim, J.-H. Lee, S.-J. Kim, G. S. Oh, H.-D. Moon, K.-B. Kwon, C. Park, B. H. Park, H.-K. Lee, S.-Y. Chung, R. Park and H.-S. So, “Roles of NADPH Oxidases in Cisplatin-Induced Reactive Oxygen Species Generation and Ototoxicity,” The Journal of Neuroscience, Vol. 30, No. 11, 2010, pp. 3933-3946.
 A. Cozzi, B. Corsi, S. Levi, P. Santambrogio, G. Biasiotto and P. Arosi, “Analysis of the Biologic Functions of H- and L-Ferritins in HeLa Cells by Transfection with siRNAs and cDNAs: Evidence for a Proliferative Role of L-Ferritin,” Blood, Vol. 103, No. 6, 2004, pp. 2377-2383.
 E. Pawelczyk, A. S. Arbab, S. Pandit, E. Hu and J. A. Frank, “Expression of Transferrin Receptor and Ferritin Following Ferumoxides-Protamine Sulfate Labeling of Cells: Implications for Cellular Magnetic Resonance Imaging,” NMR in Biomedicine, Vol. 19, 2006, pp. 581-592.
 H. M. O’Hagan, W. Wang, S. Sen, C. D. Shields, S. S. Lee, Y. W. Zhang, E. G. Clements, Y. Cai, L. Van Neste, H. Easwaran, R. A. Casero, C. L. Sears and S. B. Baylin, “Oxidative Damage Targets Complexes Containing DNA Methyltransferases, SIRT1, and Polycomb Members to Promoter CpG Islands,” Cancer Cell, Vol. 20, No. 5, 2011, pp. 606-619. http://dx.doi.org/10.1016/j.ccr.2011.09.012